Suchergebnisse
Suchergebnisse:
8. Mai 2024 · Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19. The government, the NHS or the UK Health Security Agency may choose to use these treatments in a different way from that recommended in this guidance in exceptional circumstances such as: the widespread incidence ...
- Conditions and Diseases
NICE Guidance; Browse guidance by topic. Conditions and...
- What We Do
We evaluate new health technologies for NHS use, considering...
- NICE Guidance
NICE guidance. Evidence-based recommendations for the health...
- Lifestyle and Wellbeing
NICE Guidance; Browse guidance by topic. Lifestyle and...
- News
Improved deal signals NICE recommendation of sickle cell...
- Events
Subscribe to NICE Newsletters and alerts Sign up for our...
- Meetings in Public
About public health guidelines. Scheduled meetings. No...
- Who We Are
The principles that guide the development of NICE guidance...
- Conditions and Diseases
15. Mai 2024 · Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards
21. Mai 2024 · Seit September 2023 liegt eine aktualisierte Publikation für die Betreuung Gebärender während der vaginalen Geburt vor (NICE, 2023c). Diese NICE Guideline (NG235) ersetzt die Vorgängerversion aus dem Jahr 2014 (CG190), die zuletzt 2022 überarbeitet wurde (NICE, 2014). Verschiedene Empfehlungen der Vorgängerversion (CG190 ...
8. Mai 2024 · Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19
9. Mai 2024 · NICE's guidance on tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34; replaced by this guidance) made recommendations on using the tests for people with ER-positive, HER2‑negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer (see the DG34 evidence ...
9. Mai 2024 · This guidance replaces NICE diagnostics guidance 34 (DG34) on tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. The DG34 recommendations for lymph node-negative (including micrometastatic disease) early breast cancer have been incorporated into this guidance.
